Liver transplantation in hepatocellular carcinoma - should we perform downstaging?

Znanstveni rad - Izvorni znanstveni rad

• Autor: Tajana Filipec Kanižaj
• Autor: Petra Dinjar Kujundžić
• Autor: Ana Ostojić
• Autor: Maja Mijić
• Autor: Helga Sertić Milić
• Autor: Ana Mijić
• Autor: Matija Mateljak
• Autor: Dora Martinčević
• Autor: Eva Radetić
• Autor: Vinko Vidjak
• Autor: Branislav Kocman
• Autor: Ivana Mikolašević
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Radiologija

Sažetak (engleski)

Aim: To compare the long-term outcomes between liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who were downstaged with transarterial-chemoembolization (TACE) to the Milan criteria (MC) and those initially meeting the MC.
-----
Methods: This retrospective study enrolled 198 patients with HCC: 38 were downstaged and 160 patients initially met the MC. Post-LT survival and HCC recurrence-free survival were evaluated. We assessed the association of death and HCC recurrence with TACE, baseline (age, sex, disease etiology, Model of End-stage Liver Disease, tumor number and the sum of maximum tumor diameters, waiting time, alpha-fetoprotein level) and explant characteristics (tumor number and the sum of maximum tumor diameters, micro- and macrovascular invasion).
-----
Results: The recipient survival rates one, three, and five years after LT were 88.2%, 80.1%, and 75.9%, respectively. HCC recurrence-free probabilities were 92.3%, 87.9%, and 85%, respectively. The outcomes were comparable between the groups. In multivariate analysis, the number of tumors on the explant, age, and tumor recurrence were independent risk factors for death. Only the sum of maximum tumor diameters on the explant was an independent risk factor for HCC recurrence.
-----
Conclusions: Patients successfully downstaged with TACE to the MC can achieve post-LT recipient and HCC recurrence-free survival comparable with patients initially within the MC. Good response to TACE as a criterion for LT may be a method of selecting patients with favorable biological characteristics.

• Ključne riječi (engleski): Carcinoma, Hepatocellular* / surgery; Chemoembolization, Therapeutic* / methods; Humans; Liver Neoplasms* / surgery; Liver Transplantation*; Neoplasm Recurrence, Local / pathology; Neoplasm Staging; Retrospective Studies; Treatment Outcome
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Croatian Medical Journal
• Brojčani podaci: vol. 63, br. 4, str. 317-325
• p-ISSN: 0353-9504
• e-ISSN: 1332-8166
• DOI: https://doi.org/10.3325/cmj.2022.63.317
• URN:NBN: urn:nbn:hr:105:826109
• Datum objave publikacije: 2022-08-31
• URL dokumenta: http://www.cmj.hr/2022/63/4/36046928.htm
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2022-09-22 08:13:25